Wells Fargo
SRPT icon

Wells Fargo’s Sarepta Therapeutics SRPT Stock Holding History

Wells Fargo’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,000
Closed -$1.83M – 7698
2023
Q4 		$1.83M Hold
19,000
– – ﹤0.01% 2980
2023
Q3 		$2.3M Sell
19,000
-13,200
-41% -$1.49M ﹤0.01% 2696
2023
Q2 		$3.69M Sell
32,200
-600
-2% -$77.4K ﹤0.01% 2388
2023
Q1 		$4.52M Hold
32,800
– – ﹤0.01% 2201
2022
Q4 		$4.25M Buy
32,800
+22,800
+228% +$2.64M ﹤0.01% 2202
2022
Q3 		$1.1M Hold
10,000
– – ﹤0.01% 3180
2022
Q2 		$750K Hold
10,000
– – ﹤0.01% 3480
2022
Q1 		$781K Buy
+10,000
New +$766K ﹤0.01% 4087
2021
Q2 		– Sell
-8,800
Closed -$656K – 7403
2021
Q1 		$656K Sell
8,800
-75,700
-90% -$6.99M ﹤0.01% 4533
2020
Q4 		$2.92M Buy
84,500
+82,300
+3,741% +$12.2M ﹤0.01% 3213
2020
Q3 		$55K Buy
+2,200
New +$334K ﹤0.01% 5474
2019
Q3 		– Sell
-36,700
Closed -$908K – 6697
2019
Q2 		$908K Sell
36,700
-75,100
-67% -$9.13M ﹤0.01% 3934
2019
Q1 		$146K Buy
+111,800
New +$14.4M ﹤0.01% 4974
2018
Q2 		– Sell
-15,800
Closed -$165K – 6550
2018
Q1 		$165K Buy
15,800
+9,900
+168% +$660K ﹤0.01% 5075
2017
Q4 		$3K Hold
5,900
– – ﹤0.01% 6147
2017
Q3 		$9K Buy
+5,900
New +$236K ﹤0.01% 5902

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo's SRPT Position: Q1 2026 in Review

Wells Fargo reduced its Sarepta Therapeutics (SRPT) stake by 24% in Q1 2026, selling an estimated $784K and leaving 127,200 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3018.

Wells Fargo first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $113M in Q4 2020. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Wells Fargo held 127,200 shares of Sarepta Therapeutics worth $2.77M as of Q1 2026.
  • Wells Fargo sold 40,525 Sarepta Therapeutics shares in Q1 2026, an estimated $784K.
  • Sarepta Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3018 holding.
  • Wells Fargo first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Sarepta Therapeutics position peaked at $113M in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.